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Treatment guidelines have proliferated in cardiology, although most
guideline recommendations are not supported by clinical trial evi-
dence. What is considered to be a normal cholesterol level has pro-
gressively declined over the past 50 years, with the increasing
realization that “normal” is far from optimal and that lower is better.
The ﬁrst important United States and Canadian cholesterol guidelines
were published in 1988, and recommended diet for 6 months to be
followed by consideration of bile acid sequestrants or nicotinic acid.
Over the ensuing 25 years guidelines have changed rapidly and
dramatically in response to a large number of deﬁnitive clinical trials,
usually with statins. Low-density lipoprotein cholesterol targets have
moved progressively lower, and in some guidelines, have been aban-
doned entirely. The concept of selecting patients for treatment ac-
cording to the absolute risk reduction expected from treatment on the
basis of clinical trial data seems to be a rational approach. For sec-
ondary prevention, some patients are still untreated or undertreated,
presenting an opportunity for improving outcomes.Received for publication July 5, 2018. Accepted July 25, 2018.
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Les lignes directrices sur les traitements se sont multipliees en car-
diologie, mais la plupart des recommandations qu’elles contiennent ne
sont pas appuyees par des donnees probantes recueillies dans le cadre
d’essais cliniques. La valeur consideree comme un taux de cholesterol
normal a diminue progressivement au cours des 50 dernières annees,
alors que l’on realisait de plus en plus que la valeur « normale » etait loin
d’être optimale et qu’il etait preferable de l’abaisser encore. Les pre-
mières lignes directrices importantes sur le cholesterol aux États-Unis et
au Canada ont ete publiees en 1988 et preconisaient un regime ali-
mentaire pendant 6 mois suivi d’un traitement eventuel par des chela-
teurs des acides biliaires ou par l’acide nicotinique. Au cours des 25
annees suivantes, la teneur des lignes directrices a change de façon
rapide et radicale en reponse aux resultats de plusieurs essais cliniques
determinants, portant en general sur les statines. Les cibles de choles-
terol à lipoproteines de basse densite ont vu leur importance diminuer
progressivement, jusqu’à être totalement abandonnees dans certaines
lignes directrices. Le concept de selection des patients à traiter reposant
sur la reduction du risque absolu attendue du traitement en se fondant
sur les resultats des essais cliniques semble être une approche ration-
nelle. Pour ce qui est de la prevention secondaire, il existe une possibilite
d’ameliorer l’evolution de l’etat de sante des patients puisque certains
demeurent encore non traites ou sous-traites.Nothing is different but everything’s changed.
dPaul Simon, Once Upon a Time There Was an OceanCreating rules for others to follow has been a human im-
pulse since the dawn of history. Rules, laws, and conventions
are necessary for a well functioning society, but also reﬂect the
culture and beliefs of the time. For example, one of the 282
laws in the code of Hammurabi from ancient Mesopotamiadecreed that if a doctor killed a rich patient, he would have his
hands cut off, but if he killed a slave, only ﬁnancial restitution
was required.A Short History of Medical Guidelines
Rules or guidelines in medicine are a very recent phe-
nomenon. The work of Hippocrates, On the Physician, rec-
ommended that physicians be well kempt, honest, calm,
understanding, serious, and keep their ﬁngernails at a speciﬁed
length. However, Hippocrates and Maimonides are remem-
bered primarily for their ethical precepts and not their clinical
guidelines. Published guidelines in the middle of the 20th
century were usually about medical ethics. In cardiology,
practice guidelines were relatively uncommon before 1980,
but in recent years they have proliferated. Under the searchll rights reserved.
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Cholesterol-Lowering Treatments and Targetsterm, “cardiology guidelines,” PubMed lists 31 articles for
1990, 193 for 2000, 639 for 2010, and 1445 for 2017.
Clinical trial evidence was not a prominent feature of early
cardiology guidelines. In a survey of ofﬁcial cardiology
guidelines from 1984 to 2008, the authors noted that levels of
evidence only began to be introduced in 1998.1 From 1998 to
2008, of 16 guidelines that reported levels of evidence,
comprising a total of 2711 recommendations, only 314 of
them (11%) were supported by level of evidence A. For acute
coronary syndrome, heart failure, and secondary prevention,
more than 20% of recommendations were supported by level
of evidence A, compared with < 1% of recommendations for
valvular heart disease.
In 2011 in the United States, the Institute of Medicine
published guidelines for guideline development, the main
features of which are listed in Table 1.2 Do most guidelines
meet these criteria? In a report on 114 randomly selected
guidelines published between 2006 and 2011, fewer than half
met more than 50% of the Institute of Medicine standards.3
The authors noted that no improvement in guideline quality
had occurred since a report published in 1999. Substandard
guidelines might contribute to guideline nonadherence.
A more important cause of nonadherence might be the
proliferation of guidelines. Does each related specialty in each
country or geographic region need a separate set of guidelines
on, for example, hypertension? And when multiple sets of
guidelines conﬂict,4 despite a common evidence base, does
conﬁdence in guidelines suffer?
Despite these shortcomings of guidelines, adherence to
them has been shown to improve outcomes in many common
conditions, including acute coronary syndromes,5,6 atrial
ﬁbrillation,7 and diabetes prevention.8Normal Cholesterol Levels
In the 1963 table of normal laboratory values published in
the New England Journal of Medicine, normal total cholesterol
was listed as 150-280 mg/dL (3.9-7.3 mmol/L).9 Normal
values of serum sodium, potassium, and blood glucose are still
exactly the same as they were in 1963dso what has happened
to “normal” cholesterol? Adverse consequences can be ex-
pected when serum sodium or potassium levels stray outside
of the normal range, but what was accepted as the normal
range for total cholesterol was nothing more than the average
range at that time in history in one country.Table 1. Institute of Medicine recommendations for guideline
development
The Institute of Medicine recommends that guidelines:
 Be based on a systematic review of the existing evidence
 Be developed by a knowledgeable, multidisciplinary panel of experts and
representatives from key affected groups
 Consider important patient subgroups and patient preferences, as
appropriate
 Be on the basis of an explicit and transparent process that minimizes
distortions, biases, and conﬂicts of interest
 Provide a clear explanation of the logical relationships between alternative
care options and health outcomes
 Provide ratings of the quality of evidence and the strength of the
recommendations
 Be reconsidered and revised as appropriate when important new evidence
warrants modiﬁcations of recommendationsClinical trials of cholesterol-lowering from that era were
never deﬁnitive, mainly because none of the available treat-
ments were safe and effective at lowering low-density lipo-
protein cholesterol (LDL-C). The most interesting part of
these trials from the modern perspective is the high levels of
baseline cholesterol; mean total cholesterol in primary pre-
vention trials of various diets ranged from 6.0 to 7.0 mmol/L
and in secondary prevention, from 6.5 to 8.3 mmol/L.10-16 In
none of these studies were baseline cholesterol levels used to
select patients; these were the usual adult cholesterol levels of
that era.
During 2011-2014, mean serum total cholesterol level for
United States (U.S.) adults averaged 5.0 mmol/L,17 and for
Canadian adults, 5.1 mmol/L.18 A gradual decline in
cholesterol levels in adults has occurred over the past 50 years
in most Western countries, and over the past 20 years this
trend has accelerated with increasingly widespread statin use.
To put current cholesterol levels in perspective, evidence from
premodern societies, although scant, suggests that 3.2 mmol/L
could be considered a “normal” total cholesterol for
humans.19 Data from clinical trials of cholesterol-lowering,
primarily with statins, show that lowering LDL-C reduces
cardiovascular (CV) events, with no lower limit yet detected
beyond which further LDL-C-lowering does yield further
event reduction.20A Short History of Cholesterol Guidelines
The ﬁrst report of the expert panel of the National
Cholesterol Education Program (NCEP) in the United States
was published in 1988, just before the era of statins.21 The
expert panel opined that a total cholesterol level < 200 mg/dL
(5.2 mmol/L) was “desirable,” a level of 200-239 mg/dL
(5.2-6.2 mmol/L) was borderline, and a level of 240 mg/dL
(6.2 mmol/L) or above was considered high. Dietary therapy
was the primary treatment, with drug therapy to be considered
after 6 months. Dietary therapy was recommended for pa-
tients with coronary disease or 2 other risk factors if LDL-C
was 130 mg/dL (3.4 mmol/L) or higher, with a goal of
reducing LDL-C to < 130 mg/dL. Drugs of ﬁrst choice were
bile acid sequestrants or nicotinic acid.
The report of the Canadian Consensus Conference on
Cholesterol was also published in 1988, and many of its
conclusions and recommendations were similar to those of the
NCEP expert panel.22 A total cholesterol goal of  5.2 mmol/
L was set for patients with hypercholesterolemia, with diet
being the primary therapy, and drugs to be considered after 6
months.
Cholesterol guidelines have evolved quickly and dramati-
cally since 1988 in response to a cascade of clinical trials,
usually involving statins, as shown in Figure 1. These trials
showed that cholesterol-lowering reduced CV events in at-risk
subgroups, beginning with coronary patients with hypercho-
lesterolemia, then in primary prevention subgroups, and
ﬁnally in several trials showing that more LDL-C-lowering
was preferable to less. LDL-C levels in treated patients have
decreased from considerably above 2.6 mmol/L in early statin
trials to approximately 0.8 mmol/L in recent trials testing
proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors.23
How have guideline committees responded to this tidal
wave of clinical trial data over the past 3 decades? One
Figure 1. Major trials of cholesterol-lowering drugs 1994-2018. Bars represent low-density lipoprotein cholesterol (LDL-C) at baseline. The blue
component of the bar is the LDL-C during treatment in the active treatment group, or the more intensively treated group. The red component of the
bar is the difference in LDL-C between treatment groups, or the difference between baseline and active treatment in some trials. Asterisks
represent trials in which patients were already taking statins at baseline. Note that across this 25-year time period, baseline LDL-C and LDL-C levels
during treatment have decreased. ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial; CARDS, Collaborative Atorvastatin Diabetes Study; CARE,
Cholesterol and Recurrent Events; FOURIER, Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk;
HOPE3, Heart Outcomes Prevention Evaluation 3; HPS, Heart Protection Study; IDEAL, Incremental Decrease in Endpoints Through Aggressive Lipid
Lowering; IMPROVE-IT, Improved Reduction of Outcomes: Vytorin Efﬁcacy International Trial; JUPITER, Justiﬁcation for the Use of Statins in Pre-
vention: An Intervention Trial Evaluating Rosuvastatin; LIPID, Long-Term Intervention With Pravastatin in Ischaemic Disease; MEGA,Management of
Elevated Cholesterol in the Primary Prevention Group of Adult Japanese; ODYSSEY, Long Term, Long-term Safety and Tolerability of Alirocumab in
High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy; PROSPER, Prospective
Study of Pravastatin in the Elderly at Risk; PROVE-IT, Pravastatin or Atorvastatin Evaluation and Infection Therapy; 4S, Scandinavian Simvastatin
Survival Study; SEARCH, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; SHARP, Study Heart and Renal
Protection; SPARCL, Stroke Prevention by Aggressive Reduction in Cholesterol Levels; TNT, Treating to New Targets; WOSCOPS,West of Scotland
Coronary Prevention Study.
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Volume 35 2019response has been to continue to lower LDL-C targets; for
example, the LDL-C target of 70 mg/dL (1.8 mmol/L) was
introduced in 2004 as a therapeutic option for very high-risk
patients, going beyond the 2001 NCEP recommendations,24
but has since been adopted as a much broader target. The
most recent American Association of Clinical Endocrinolo-
gists/American College of Endocrinology guidelines establish
5 levels of risk from low to extreme with 5 corresponding
LDL-C targets, from 130 mg/dL (3.4 mmol/L) to 55 mg/dL
(1.4 mmol/L).25
In addition to ﬁxed numerical targets, some guidelines have
introduced a percent reduction in baseline LDL-C, either as a
component of the target, or as a stand-alone goal. For example,
the current Canadian guidelines recommend a target LDL-C of
< 2 mmol/L or a > 50% reduction in LDL-C for interme-
diate- or high-risk patients. For patients with a LDL-C > 5
mmol/L, a > 50% reduction is recommended as a stand-alone
target.26 The evidence supports percent reduction as superior
to ﬁxed LDL-C targets. In a study speciﬁcally comparing them,
percent LDL-C reduction added incremental prognostic value
over statin dose and attained LDL-C levels, but attained
LDL-C level did not provide incremental prognostic value over
statin dose and percent LDL-C reduction.27
The most recent European guidelines also include a
percent reduction goal.28 They go further however, and for
the ﬁrst time question the value of numerical targets:“lowering LDL-C beyond the goals that were set in the pre-
vious EAS/ESC guidelines is associated with fewer CV events.
Therefore, it seems appropriate to reduce LDL-C as low as
possible, at least in patients at very high CV risk.”28
The 2013 American College of Cardiology (ACC)/Amer-
ican Heart Association (AHA) guidelines took the radical step
of eliminating LDL-C targets.29 Instead, 4 treatment groups
were identiﬁed for which clinical trial evidence showed that
statins reduced number of events. High- or moderate-intensity
statin treatment was recommended for all patients without
contraindications. High-intensity treatment was deﬁned as a
drug and dose that reduced LDL-C by  50%, and moderate-
intensity treatment as that yielding a 30% to < 50%
reduction.
The National Institute for Health and Care Excellence in
the United Kingdom recommends a speciﬁc statin, atorvas-
tatin, at either the 10 mg or 80 mg dose, depending upon the
level of risk.30 The Kidney Disease: Improving Global Out-
comes guideline makes the important point that LDL-C is not
an accurate predictor of CV risk in patients with chronic
kidney disease, and should not be used to determine who
should receive lipid-lowering treatment.31 The Kidney Dis-
ease: Improving Global Outcomes guideline also recommends
a statin, with or without ezetimibe, for all adults aged 50 years
or older with chronic kidney disease, and for those aged 18-49
years with a 10-year CV risk > 10%.
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guidelines, proposals have been advanced for patient selection
criteria for cholesterol-lowering treatment. Ridker and col-
leagues suggested that the ACC/AHA algorithm incorporate
groups that have been shown to derive clear beneﬁt in 5 major
primary prevention trials.32 These investigators pointed out
that for primary prevention, the ACC/AHA guidelines and
trial-derived selection criteria identiﬁed groups that overlap
only partly. Trial-based patient selection also does not force
treatment consideration for most elderly participants, whose
10-year risk almost automatically exceeds 7.5%. At the other
extreme, it has been advocated that age alone be used to select
individuals for statin therapy; that is, simply to treat everyone
beginning at age 55 years.33 This approach is cost-effective
because it does not require laboratory measurement of lipids
or drug titration to targets.
Cholesterol guidelines have evolved dramatically since
1988. The pool of individuals shown in clinical trials to
beneﬁt from cholesterol-lowering has increased substantially.
Reassuringly, statins have been remarkably safe,20 and are now
comparatively inexpensive, making them cost-effective for
lower-risk subgroups. Guidelines have thus expanded to
include more patients. Combination cholesterol-lowering
regimens that include a PCSK9 inhibitor are capable of
lowering LDL-C levels to well below 1 mmol/L.Speciﬁc Numerical LDL-C Targets
Early cholesterol guidelines contained speciﬁc cut points
for initiation of treatment and as treatment targets; specif-
ically, 190, 160, 130, 100, and 70 mg/dL (4.9, 4.1, 3.4, 2.6,
and 1.8 mmol/L).4 These numbers are not on the basis of any
clinical trial evidence. The evidence indicates that statins
reduce CV events in a linear fashion across a broad range of
LDL-C down to a level < 1.3 mmol/L.20,34 There is nothing
magical about the target numbers. In a post hoc analysis from
the Further Cardiovascular Outcomes Research With PCSK9
Inhibition in Subjects With Elevated Risk (FOURIER) trial,
evolocumab reduced the risk of the primary end point by 20%
(hazard ratio [HR], 0.80; 95% conﬁdence interval [CI], 0.60-
1.07) in the 2034 patients with a baseline LDL-C < 1.8
mmol/L and by 14% (HR, 0.86; 95% CI, 0.79-0.92) in those
with a baseline LDL-C  1.8 mmol/L.35,36 High-risk patients
with an LDL-C < 1.8 mmol/L beneﬁt from further LDL-C
reduction.
The strategy of treating to a speciﬁc LDL-C target has been
recommended for many years in various guidelines, but until
recently had not actually been rigourously tested in an adequately
powered clinical trial. In the Standard vs Intensive Statin Ther-
apy For Hypercholesterolemic Patients With Diabetic Reti-
nopathy (EMPATHY) trial, 5042 patients in Japan were
randomized to either standard therapy targeting an LDL-C level
of 100-120 mg/dL (2.6-3.1 mmol/L) or to more intensive
therapy, targeting an LDL-C< 70 mg/dL (1.8 mmol/L).37 The
LDL-C range of 100-120 mg/dL is in accord with cholesterol
guidelines in Japan. After a median follow-up of approximately 3
years, the CV event rate was reduced, but not signiﬁcantly, in the
intensive group (HR, 0.84; 95% CI, 0.67-1.07). However, less
than half of the patients in the intensive therapy group actually
attained the LDL-C target of< 70mg/dL (1.8 mmol/L), and in
an analysis restricted to patients who actually achieved theirLDL-Cgoals, a large reduction inCV events was seen (HR, 0.48;
95% CI, 0.28-0.82).
The failure of physicians to get more than half of patients
to goal during 3 years of treatment within the strict conﬁnes
of a clinical trial suggests that the whole strategy of treating to
a target is impractical and ﬂawed. Because Japanese physicians
tend to prescribe smaller doses of statins (and other drugs)
compared with physicians in most other countries, it is
possible that a higher proportion of patients might have
attained their target if the trial had been performed elsewhere.
Nevertheless, in the absence of any credible evidence that the
treating to target approach works, it seems reasonable that
guideline committees stop recommending it.Selecting Patients for Cholesterol-Lowering
Treatment
Physicians have gradually learned to treat the level of CV
risk instead of treating the level of cholesterol, despite the dif-
ﬁculties in accurately assessing risk. A more precise approach to
patient selection involves the calculation of absolute risk
reduction (ARR).38,39 ARR can be calculated for an individual
if one knows the baseline LDL-C level, the baseline level of risk,
and the amount of LDL-C reduction with treatment. With
statins, each mmol/L reduction in LDL-C reduces CV events
by 22%.20 Statins reduce LDL-C as a percentage of the baseline
level, so that a 50% LDL-C reduction will reduce risk more
when baseline LDL-C is high compared with low.
For primary prevention, the ACC/AHA guidelines
recommend consideration of treatment for subjects with a 10-
year risk of  7.5% and an LDL-C of 70-189 mg/dL (1.8-4.9
mmol/L).29 Thanassoulis et al. have described a “beneﬁt-
based” approach derived from the results of primary preven-
tion trials, and using a 10-year ARR of 2.3 as the decision
point for treatment.39 The beneﬁt-based approach identiﬁed
9.5 million Americans not currently eligible for statin treat-
ment because their 10-year risk was < 7.5%, who had the
same or greater expected beneﬁt from statins compared with
higher-risk individuals (a 10-year ARR of 2.3). Using this
approach on the basis of the beneﬁts seen in trials leads to a
more precise targeting of patients who will beneﬁt from
cholesterol-lowering.
Older guidelines recommended more intensive treatment
to attain lower treatment goals in patients with higher levels of
risk, and less intensive treatment and easier goals for patients
in lower-risk categories. Because, with the exception of sim-
vastatin, adverse effects of statins are not closely related to
dose,40 and lower attained LDL-C levels yield more event
reduction,20 low-intensity statin therapy does not make sense
for patients who tolerate higher doses.Selecting Patients for Combined Cholesterol-
Lowering Treatment
Fibrates and niacin did not reduce CV events in clinical
trials of patients taking statins, and thus are no longer rec-
ommended as add-on therapy in current guidelines.26,28-30
Ezetimibe is commonly used as add-on therapy on the basis
of the results of the Improved Reduction of Outcomes:
Vytorin Efﬁcacy International Trial (IMPROVE-IT),41 in
which 18,144 post-acute coronary syndrome patients were
594 Canadian Journal of Cardiology
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10 mg/d. After 7 years of follow-up, the primary end point
was 32.7% in the combination therapy group and 34.7% in
the simvastatin-alone group, a 6.4% relative risk reduction
(P ¼ 0.016). The number need to treat to prevent one CV
event in IMPROVE-IT was 350 per year of treatment. The
application to approve the simvastatin/ezetimibe combination
for the reduction of CV events was rejected by the U.S. Food
and Drug Administration, but was approved by the European
Medicines Agency. Subgroup analyses of IMPROVE-IT
showed a signiﬁcant CV event reduction in patients with
diabetes and in those aged 75 years or older, but none in
nondiabetic patients or patients younger than 75 years of
age.42
European and Canadian guidelines recommend that
consideration be given to using ezetimibe in addition to a
statin in selected patients who do not reach treatment targets
with statins alone.26,28 The ACC Task Force on Clinical
Expert Consensus Documents published an “expert consensus
decision pathway on the role of nonstatin therapies for LDL-
C-lowering.”43 The Task Force emphasized that they did not
use the rigourous methodology required for guideline devel-
opment, and also recommended that ezetimibe be considered
for patients with an inadequate response to statin therapy.
Two large clinical trials have recently shown that the PCSK9
inhibitors evolocumab and alirocumab not only reduce LDL-C
by more that 50% but also correspondingly reduce CV
events.44,45 Because of to their high cost, PCSK9 inhibitors
have been determined in studies from various groups to be far
from cost-effective for most patients, as recently summarized by
Annemans et al.46 However, patients with a 10-year risk of a
CV event in the range of 30% despite statin treatment have
been identiﬁed from subgroup analyses of clinical trials.47
These subgroups and their estimated levels of risk are listed
in Table 2. The phrase, “highest risk-highest beneﬁt” has been
coined to deﬁne the patients likely to beneﬁt from PCSK9
inhibitor treatment and to meet cost-effectiveness criteria.46
This relationship is depicted in Figure 2.Tools to Improve the Accuracy of Risk
Assessment
Treatment decisions depend on accurate risk assessment,
and the inaccuracy of standard risk assessment tools might beTable 2. Patient subgroups with a very high 10-year risk despite statin
treatment
Patient category 10-year risk, %
Clinical ASCVD and diabetes 28-38
With CKD 28-43
Without CKD 26-29
Clinical ASCVD and CKD 34-35
Recent ACS (< 3 months) 32
CHD and poorly controlled risk factors 28-41
CHD and CKD 43-55
CHD and age 65 years or older 21-54
Male sex and stroke or TIA 31
CHD and baseline LDL-C  5.0 mmol/L 41
ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular
disease; CHD, coronary heart disease; CKD, chronic kidney disease; LDL-C,
low-density lipoprotein cholesterol; TIA, transient ischemic attack.
Data from Robinson et al.47the Achilles heel that limits accurate treatment decisions.
A subgroup within a population might have a risk that differs
substantially from the mean risk of the entire population. Risk
has shifted over time, and data from older cohorts might not
accurately reﬂect current risk.
Nontraditional risk factors are potentially useful tools to
increase the precision of risk prediction, such that cholesterol-
lowering treatment could be targeted to patients with a high
likelihood of beneﬁt, while avoiding those truly at very low
risk. The evidence for 3 popular nontraditional risk factors,
coronary artery calcium (CAC) score, high-sensitivity
C-reactive protein (hs-CRP), and ankle-brachial index
(ABI), was recently reviewed by a panel from the U.S. Pre-
ventive Services Task Force.48-50 The panel concluded that
there is insufﬁcient evidence at this time to recommend for or
against adding CAC score, hs-CRP level, or ABI to traditional
risk assessment for CV disease in asymptomatic adults to
prevent CV disease events.
This general conclusion does not preclude these tests from
being useful in speciﬁc types of patients. A CAC score > 100
Agatston units reclassiﬁes a patient with a borderline risk to
high-risk, and conversely, a score of 0 reclassiﬁes the same in-
dividual to a low-risk group. Reclassiﬁcation studies consistently
show across different race and sex groups that CAC score pro-
vides useful risk stratiﬁcation information when applied to pa-
tients for whom the question of statin treatment is uncertain.50
A high hs-CRP level is a marker of increased CV risk;
however, the effect of hs-CRP level on risk reclassiﬁcation is
modest, and thus the usefulness of hs-CRP measurement in
routine assessment of CV disease risk for primary prevention
is limited.50
ABI is a well validated test to detect peripheral arterial
disease; indeed, a low ABI indicates severe atherosclerosis and
warrants consideration of statin treatment, even in the absence
of other risk factors. However, ABI adds little value to tradi-
tional risk factor assessment.48-50 A low ABI is uncommon in
the absence of other risk factors and a normal ABI does not
meaningfully reclassify a subject with risk factors to a lower
risk category.Practical Considerations
Most of the information in this article is not relevant to the
day-to-day work of a practicing cardiologist because most of
the patients that we see already have atherosclerosis, and ac-
cording to any cholesterol guideline, should be treated
aggressively. Yet, evidence suggests that many of our patients
do not receive guideline-recommended treatment. In a large
series of patients older than 65 years in Ontario, 33.9% were
receiving optimal medical therapy, deﬁned as a statin, a b-
blocker, and either an angiotensin-converting enzyme inhib-
itor or angiotensin receptor blocker, before percutaneous
coronary intervention, but only 47.1% were receiving such
therapy after percutaneous coronary intervention.51 The
proportion receiving a statin increased from 64.3% to 84.6%.
Data on persistence of treatment with a statin is worse. In
an older study, more than half of patients in British Columbia
who were prescribed a statin discontinued it for at least 90
days during follow-up.51 Patients who discontinue their statin
are signiﬁcantly more likely to experience myocardial infarc-
tion and CV death.52 Should we blame patients for
Figure 2. “Highest riskehighest beneﬁt” strategy for proprotein convertase subtilisin/kexin 9 inhibitor use. The schematic shows low-density lipo-
protein cholesterol (LDL-C) during optimum statin/ezetimibe therapy on the vertical axis and cardiovascular risk on the horizontal axis. Predicted
relative risk reduction (RRR) associated with a proprotein convertase subtilisin/kexin 9 inhibitor-induced 60% decrease in LDL-C is in the ﬁrst column.
This is on the basis of a 22% risk reduction per 1.0mmol/L decrease in LDL-C as conﬁrmed in Further CardiovascularOutcomesResearchWith PCSK9
Inhibition in Subjects With Elevated Risk (FOURIER). Number needed to treat (NNT) is provided per 5% increment in risk and 1.0 mmol/L increment in
LDL-C in the other columns. These are given for a 5-year time scale. Varying cost proﬁles are represented by the shades of green. A low-cost jurisdiction
might permit NNT< 30 as an acceptable threshold; medium-cost NNT< 20; and high-cost NNT< 15. For illustration purposes, markers are provided
for the approximate NNT for the average FOURIER subject (FA; estimated annual risk 3.3%), a FOURIER subject in the top LDL-C quartile (F4; annual risk
3.8%), and the National Institute for Health and Care Excellence-approved categories (NVH: very high risk [ie, polyvascular disease or multiple events,
LDL-C> 3.5 mmol/L]; NFH: FH no event with LDL-C> 5.0 mmol/L). Reproduced from Annemans et al.
46 with permission from Oxford University Press.
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effects of statins from many sources, and any fears that they
have will often be magniﬁed by lurid, inaccurate information
that chokes the internet.53
Who will tell our patients with coronary disease that the
biggest threat to their health is CV disease and its complica-
tions? And that if their LDL-C is reduced by > 2 mmol/L,
their risk of myocardial infarction, stroke, coronary revascu-
larization, and CV death will all be reduced by half? Do we
have something more important than this to do during the
brief minutes we have with each patient? For the patient with
previous coronary bypass surgery who has been happily taking
a low-dose statin ever since, can we take the time to switch to
high-intensity therapy? The ARR over 5 years for such a
switch is 3.3 for a major CV event and an additional 4.6 for
repeat revascularization.54 Few things that we do in practice
accomplish that much beneﬁt with such little effort.
Nothing is different but everything’s changed. The
guidelines have changed substantially over the past 2 decades,
but nothing is different about the challenges we face in termsof providing optimal cholesterol-lowering therapy to our pa-
tients, and maintaining their adherence.Disclosures
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